Lipid nanoemulsions loaded with doxorubicin-oleic acid ionic complex: Characterization, in vitro and in vivo studies

Pharmazie

Volumn 66, Issue 7, 2011, Pages 496-505

  Zhang, Xuanmiao ^a   Sun, Xun ^a   Li, Jilong ^a   Zhang, Xiaoning ^b   Gong, Tao ^a   Zhang, Zhirong ^a  

^a SICHUAN UNIVERSITY   (China)

^b Tsinghua University   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; OLEIC ACID; ANTINEOPLASTIC ANTIBIOTIC; COLORING AGENT; DRUG CARRIER; NANOPARTICLE; OCTANOL; TETRAZOLIUM; THIAZOLE DERIVATIVE; THIAZOLYL BLUE; WATER;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG RELEASE; DRUG SOLUBILITY; DRUG TISSUE LEVEL; DRUG UPTAKE; FLOW CYTOMETRY; IN VITRO STUDY; IN VIVO STUDY; KIDNEY; LIPOPHILICITY; LIVER; LUNG; MALE; MOUSE; NANOEMULSION; NONHUMAN; PARTICLE SIZE; PHYSICOCHEMICAL MODEL; PLASMA CONCENTRATION-TIME CURVE; SPLEEN; ZETA POTENTIAL; ANIMAL; CELL SURVIVAL; CHEMISTRY; CONFOCAL MICROSCOPY; DRUG EFFECT; DRUG FORMULATION; ELECTROCHEMISTRY; EMULSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; SOLUBILITY; TISSUE DISTRIBUTION; TRANSMISSION ELECTRON MICROSCOPY; TUMOR CELL LINE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CELL LINE, TUMOR; CELL SURVIVAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COLORING AGENTS; DOXORUBICIN; DRUG CARRIERS; DRUG COMPOUNDING; ELECTROCHEMISTRY; EMULSIONS; FLOW CYTOMETRY; HUMANS; MALE; MICE; MICROSCOPY, CONFOCAL; MICROSCOPY, ELECTRON, TRANSMISSION; NANOPARTICLES; OCTANOLS; OLEIC ACID; PARTICLE SIZE; SOLUBILITY; TETRAZOLIUM SALTS; THIAZOLES; TISSUE DISTRIBUTION; WATER;

EID: 80051947376     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2011.0379     Document Type: Article

References (46)

1. Bali V, Ali M, Ali J (2010) Study of surfactant combinations and development of a novel nanoemulsion for minimising variations in bioavailability of ezetimibe. Colloids Surf B Biointerfaces 76: 410-420.
2. Cavalli R, Caputo O, Gasco MR (1993) Solid lipospheres of doxorubicin and idarubicin. Int J Pharm 89: R9- R12.
3. Fundarò A, Cavalli R, Bargoni A, Vighetto D, Zara GP, Gasco MR (2000) Non-stealth and stealth solid lipid nanoparticles (SLN) carrying doxorubicin: pharmacokinetics and tissue distribution after i.v. administration to rats. Pharmacol Res 42: 337-343.
4. Gutierrez JM, Gonzalez C, Maestro A, Sole I, Pey CM, Nolla J (2008) Nanoemulsions: new applications and optimization of their preparation. Curr Opin Colloid Interface Sci 13: 245-251. (Pubitemid 351818213)
5. Higashiyama M, Inada K, Ohtori A, Kakehi K (2007) NMR analysis of ion pair formation between timolol and sorbic acid in ophthalmic preparations. J Pharm Biomed Anal 43: 1335-1342. (Pubitemid 46282381)
6. Huynh NT, Passirani C, Saulnier P, Benoit JP (2009) Lipid nanocapsules: a new platform for nanomedicine. Int J Pharm 379: 201-209.
7. Joshi MD, Müller RH (2009) Lipid nanoparticles for parenteral delivery of actives. Eur J Pharm Biopharm 71: 161-172.
8. Kalinkova GN (2007) Complexation: Non-Cyclodextrins. In: Swarbrick J (ed.) Encyclopedia of pharmaceutical technology, 3rd ed., New York, p. 697-706.
9. Li J, Nie S, Yang X, Wang C, Cui S, Pan W (2008) Optimization of tocol emulsions for the intravenous delivery of clarithromycin. Int J Pharm 356: 282-290.
10. Li X, Ding L, Xu Y, Wang Y, Ping (2009) Targeted delivery of doxorubicin using stealth liposomes modified with transferrin. Int J Pharm 373: 116-123.
11. Ma P, Dong X, Swadley CL, Gupte A, Leggas M, Ledebur HC, Mumper RJ (2009) Development of idarubicin and doxorubicin solid lipid nanoparticles to overcome Pgp-mediated multiple drug resistance in leukemia. J Biomed Nanotechnol 5: 151-161.
12. Mehnert W, Mäder K (2001) Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev 47: 165-196. (Pubitemid 32324113)
13. Moghimi SM, Hunter AC, Murray JC (2001) Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol. Rev 53: 283-318. (Pubitemid 32476118)
14. Moghimi SM, Szebeni J (2003) Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog Lipid Res 42: 463-478. (Pubitemid 37237636)
15. Montero MT, Freixas J, Hermindez-Borrell J (1997) Expression of the partition coefficients of a homologous series of 6-fluoroquinolones. Int J Pharm 149: 161-170. (Pubitemid 27193402)
16. Mosqueira VC, Legrand P, Gulik A, Bourdon O, Gref R, Labarre D, Barratt G (2001) Relationship between complement activation, cellularuptake and surface physicochemical aspects of novel PEG-modified nanocapsules. Biomaterials 22: 2967-2979. (Pubitemid 32768704)
17. Mou D, Chen H, Du D, Mao C, Wan J, Xu H, Yang X (2008) Hydrogelthickened nanoemulsion system for topical delivery of lipophilic drugs. Int J Pharm 353: 270-276.
18. Müller RH, Mäder K, Gohla S (2000) Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm 50: 161-177. (Pubitemid 30326695)
19. Olbrich C, Gessner A, Kayser O, Müller RH (2002) Lipid-drug conjugate (LDC) nanoparticles as novel carrier system for the hydrophilic antitrypanosomal drug diminazenediaceturate. J Drug Target 10: 387-396.
20. Olbrich C, Gessner A, Schröder W, Kayser O, Müller RH (2004) Lipid-drug conjugate nanoparticles of the hydrophilic drug diminazene- cytotoxicity testing and mouse serum adsorption. J Control Release 96: 425-435. (Pubitemid 38553921)
21. Park J, Fong PM, Lu J, Russell KS, Booth CJ, Saltzman WM, Fahmy TM (2009) PEGylated PLGA nanoparticles for the improved delivery of doxorubicin. Nanomedicine 5: 410-418.
22. Petri B, Bootz A, Khalansky A, Hekmatara T, Müller R, Uhl R, Kreuter J, Gelperina S (2007) Chemotherapy of brain tumour using doxorubicin bound to surfactant-coated poly (butyl cyanoacrylate) nanoparticles: revisiting the role of surfactants. J Control Release 117: 51-58. (Pubitemid 46164866)
23. Pontes-Arruda A (2009) Biological benefits of an oleic acid-rich lipid emulsion for parenteral nutrition. Clin Nutr Suppl 4: 19-23.
24. Prabaharan M, Grailer JJ, Pilla S, Steeber DA, Gong S (2009) Folate-conjugated amphiphilic hyperbranched block copolymers based on Boltorn H40, poly(L-lactide) and poly(ethylene glycol) for tumor-targeted drug delivery. Biomaterials 30: 3009-3019.
25. Quintanar-Guerrero D, Allemann E, Fessi H, Doelker E (1997) Applications of the ion-pair concept to hydrophilic substances with special emphasis on peptides. Pharm Res 14: 119-127. (Pubitemid 27146352)
26. Santos-Magalhaes NS, Pontes A, Pereira VMW, Caetano MNP (2000) Colloidal carriers for benzathine penicillin G: Nanoemulsions and nanocapsules. Int J Pharm 208: 71-80.
27. Singal PK, Li T, Kumar D, Danelisen I, Iliskovic N (2000) Adriamycin induced heart failure: mechanism and modulation. Mol Cell Biochem 207: 77-86.
28. Singh KK,Vingkar SK (2008) Formulation, antimalarial activity and biodistribution of oral lipid nanoemulsion of primaquine. Int J Pharm 347: 136-143. (Pubitemid 350180322)
29. Solans C, Izquierdo P, Nolla J, Azemar N, Garcia-Celma MJ (2005) Nanoemulsions. Curr Opin Colloid Interface Sci 10: 102-110.
30. Sonneville-Auburn O, Simonnet JT, L'Alloret F (2004) Nanoemulsions: a new vehicle for skin care products. Adv Colloid Interface Sci 108-109: 145-149.
31. Subedi RK, Kang KW, Choi HK (2009) Preparation and characterization of solid lipid nanoparticles loaded with doxorubicin. Eur J Pharm Sci 37: 508-513.
32. Sznitowska M, Zurowska-Prychkowska K, Janicki S, Jarviuen T (1999) Miotic effect and irritation potential of pilocarpine prodrug incorporated into a submicron emulsion vehicle. Int J Pharm 184: 115-120. (Pubitemid 29309001)
33. Upadhyay KK, Bhatt AN, Mishra AK, Dwarakanath BS, Jain S, Schatz C, Le Meins JF, Farooque A, Chandraiah G, Jain AK, Misra A, Lecommandoux S (2010) The intracellular drug delivery and anti tumor activity of doxorubicin loaded poly (gamma-benzyl L-glutamate)-b-hyaluronan polymersomes. Biomaterials 31: 2882-2892.
34. Vonarbourg A, Passirani C, Saulnier P, Benoit JP (2006) Parameters influencing the stealthiness of colloidal drug delivery systems. Biomaterials 27: 4356-4373. (Pubitemid 43674179)
35. Vyas TK, Shahiwala A, Amiji MM (2008) Improved oral bioavailability and brain transport of Saquinavir upon administration in novel nanoemulsion formulations. Int J Pharm 347: 93-101. (Pubitemid 350180312)
36. Wissing SA, Kayser O, Müller RH (2004) Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev 56: 1257-1272. (Pubitemid 38510473)
37. Wolfram G, Adolph M, Eckart J (1989) Distribution and elimination of mediumand long-chain fatty acids of a fat emulsion in lipoproteins of severely injured patients following bolus injection. Z Ernahrungswiss 28: 173-180. (Pubitemid 19163958)
38. Working PK, Newman MS, Huang SK, Mayhew E, Vaage J, Lasic DD (1994) Pharmokinetics, biodistribution and therapeutic efficacy of doxorubicin encapsulated in Stealth liposomes (Doxil®) . J Liposome Res 4: 667-687. (Pubitemid 24130564)
39. Xiong XB, Huang Y, Lu WL, Zhang X, Zhang H, Nagai T, Zhang Q (2005) Enhanced intracellular delivery and improved antitumor efficacy of doxorubicin by sterically stabilized liposomes modified with a synthetic RGD mimetic. J Control Release 107: 262-275. (Pubitemid 41316289)
40. Yilmaz E, Borchert HH (2005) Design of a phytosphingosine-containing positively charged nanoemulsion as a colloidal carrier system for dermal application of ceramides. Eur J Pharm Biopharm 60: 91-98. (Pubitemid 40545865)
41. Young RC, Ozols RF, Myers CE (1981) The anthracycline antineoplastic drugs. N Engl J Med 305: 139-153. (Pubitemid 11073081)
42. Yue PF, Yuan HL, Li XY, Yang M, Zhu WF, Xiao XH (2007) Development and optimization of intravenous puerarin emulsions formation by a novel complex-phase inversion-homogenization technology. Chem Pharm Bull 55: 1563-1568. (Pubitemid 350126161)
43. Zhang J, Chen XG, Li YY, Liu CS (2007) Self-assembled nanoparticles based on hydrophobically modified chitosan as carriers for doxorubicin. Nanomedicine 3: 258-265. (Pubitemid 350192330)
44. Zhang YF,Wang JC, Bian DY, Zhang X, Zhang Q (2010) Targeted delivery of RGD-modified liposomes encapsulating both combretastatin A-4 and doxorubicin for tumor therapy: in vitro and in vivo studies. Eur J Pharm Biopharm 74: 467-473.
45. Zhao D, Gong T, Fu Y, Nie Y, He LL, Liu J, Zhang ZR (2008) Lyophilized Cheliensisin A submicron emulsion for intravenous injection: characterization, in vitro and in vivo antitumor effect. Int J Pharm 357: 139-147.
46. Zheng C, Qiu L, Yao X, Zhu K (2009) Novel micelles from graft polyphosphazenes as potential anti-cancer drug delivery systems: drug encapsulation and in vitro evaluation. Int J Pharm 373: 133-140.